T
Torben Plesner
Researcher at University of Southern Denmark
Publications - 205
Citations - 11134
Torben Plesner is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Daratumumab & Multiple myeloma. The author has an hindex of 45, co-authored 186 publications receiving 9295 citations. Previous affiliations of Torben Plesner include University of Copenhagen & Finsen Laboratory.
Papers
More filters
Journal ArticleDOI
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
TL;DR: Platelets and megakaryocytes contain functional nuclear factor-{kappa}B andalpha-granule release, and signaling cells in the immune continuum.
Journal ArticleDOI
Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival
Peter M. Voorhees,Valeria Magarotto,Pieter Sonneveld,Torben Plesner,Ulf-Henrik Mellqvist,Claudia E. Paba-Prada,Catriona Byrne,Johan Harmenberg,Eva Nordström,Antonio Palumbo,Paul G. Richardson +10 more
TL;DR: The primary objective of Phase 2a of melflufen is the overall response rate and safety of the MTD in a total of 55 patients, and response was rapid with 93% of patients achieving ≥ MR after 1-3 cycles and 64% achieving PR after only 1- 3 cycles.
P09 daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (ndmm): updated analysis of the phase 3 maia study
Katja Weisel,S Kisore Kumar,Philippe Moreau,N. Bahlis,Thierry Facon,Torben Plesner,R. Orlowski,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,A. Perrot,Chritopher Venner,NS Raje,Margaret Macro,Laurent Frenzel,Xavier Leleu,Huiling Pei,Maria Krevvata,Robin Carson,Fredrik Borgsten,S. Usmani +23 more
TL;DR: This article performed a comprehensive literature search and meta-analysis, including studies listed in Embase and PubMed (01/01/2010 01/11/2022) on SliM CRAB positive pts, including digitizable progression curves that would allow generation of individualized data.
Journal Article
A novel fully human anti-CD20 monoclonal antibody: First clinical results from an ongoing phase I/II trial in patients with follicular non-Hodgkin's lymphoma
Journal ArticleDOI
Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies
TL;DR: The opportunities provided by facilitated subcutaneous immunoglobulin administration (fSCIg) to treat patients for whom the conventional routes (intravenous and sub cutaneous) are sub-optimal are studied.